PubRank

John P Hoffman

Author PubWeight™ 76.27‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Fluorouracil vs gemcitabine chemotherapy before and after fluorouracil-based chemoradiation following resection of pancreatic adenocarcinoma: a randomized controlled trial. JAMA 2008 7.07
2 Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol 2009 2.88
3 Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704. J Clin Oncol 2008 2.81
4 Failure to adhere to protocol specified radiation therapy guidelines was associated with decreased survival in RTOG 9704--a phase III trial of adjuvant chemotherapy and chemoradiotherapy for patients with resected adenocarcinoma of the pancreas. Int J Radiat Oncol Biol Phys 2011 2.54
5 Fluorouracil-based chemoradiation with either gemcitabine or fluorouracil chemotherapy after resection of pancreatic adenocarcinoma: 5-year analysis of the U.S. Intergroup/RTOG 9704 phase III trial. Ann Surg Oncol 2011 2.38
6 Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma. Ann Surg Oncol 2004 2.27
7 Full-dose gemcitabine with concurrent radiation therapy in patients with nonmetastatic pancreatic cancer: a multicenter phase II trial. J Clin Oncol 2008 2.15
8 A multi-institutional phase II trial of preoperative full-dose gemcitabine and concurrent radiation for patients with potentially resectable pancreatic carcinoma. Ann Surg Oncol 2006 2.10
9 Pancreatic Adenocarcinoma, version 2.2012: featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2012 1.97
10 Defining venous involvement in borderline resectable pancreatic cancer. Ann Surg Oncol 2010 1.93
11 Phase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132. Ann Surg Oncol 2011 1.86
12 Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer 2006 1.72
13 Frequent activation of AKT2 kinase in human pancreatic carcinomas. J Cell Biochem 2002 1.70
14 The metastatic/examined lymph node ratio is an important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. Am Surg 2004 1.57
15 Laparoscopic pancreatoduodenectomy: a review of 285 published cases. Ann Surg Oncol 2011 1.54
16 Pancreatic adenocarcinoma. J Natl Compr Canc Netw 2010 1.52
17 Nonneoplastic celiac axis occlusion in patients undergoing pancreaticoduodenectomy. Am J Surg 2007 1.39
18 Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas 2008 1.38
19 Proteomic analyses of pancreatic cyst fluids. Pancreas 2009 1.29
20 En bloc resection for locally advanced cancer of the pancreas: is it worthwhile? J Gastrointest Surg 2002 1.26
21 An iPSC line from human pancreatic ductal adenocarcinoma undergoes early to invasive stages of pancreatic cancer progression. Cell Rep 2013 1.21
22 A challenge to the therapeutic nihilism of ESPAC-1. Int J Radiat Oncol Biol Phys 2005 1.14
23 CA 19-9 levels predict results of staging laparoscopy in pancreatic cancer. J Gastrointest Surg 2005 1.13
24 The influence of total nodes examined, number of positive nodes, and lymph node ratio on survival after surgical resection and adjuvant chemoradiation for pancreatic cancer: a secondary analysis of RTOG 9704. Int J Radiat Oncol Biol Phys 2010 1.05
25 Chemoradiation followed by chemotherapy before resection for borderline pancreatic adenocarcinoma. Am J Surg 2008 1.03
26 Pancreatic resection for locally advanced primary and metastatic nonpancreatic neoplasms. Am Surg 2002 1.02
27 Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res 2004 1.02
28 Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer 2003 1.01
29 Survival after pancreatectomy with major arterial resection and reconstruction. Ann Surg Oncol 2008 0.99
30 Initial experience with laparoscopic hepatic resection at a comprehensive cancer center. Surg Endosc 2011 0.99
31 Significance of pathologic response to preoperative therapy in pancreatic cancer. Ann Surg Oncol 2011 0.99
32 Laparoscopic radical cholecystectomy and Roux-en-Y choledochojejunostomy for gallbladder cancer. Surg Endosc 2010 0.95
33 Peritoneal cytology in patients with potentially resectable adenocarcinoma of the pancreas. Am Surg 2004 0.93
34 Preoperative chemoradiation therapy for adenocarcinoma of the pancreas: The Fox Chase Cancer Center experience, 1986-2003. Surg Oncol Clin N Am 2004 0.91
35 Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas. Am Surg 2002 0.90
36 Laparoscopic completion radical cholecystectomy for T2 gallbladder cancer. Surg Endosc 2010 0.90
37 Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother 2006 0.86
38 Significance of common hepatic artery lymph node metastases during pancreaticoduodenectomy for pancreatic head adenocarcinoma. Ann Surg Oncol 2007 0.85
39 Neoadjuvant therapy in pancreatic cancer. Cancer Invest 2007 0.85
40 Pancreatic adenocarcinoma: Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2005 0.85
41 Video: laparoscopic Whipple procedure with a two-layered pancreatojejunostomy. Surg Endosc 2011 0.84
42 The anatomic course of the first jejunal branch of the superior mesenteric vein in relation to the superior mesenteric artery. Int J Surg Oncol 2012 0.83
43 Potential prognostic biomarkers of pancreatic cancer. Pancreas 2014 0.83
44 Is reporting of recurrence data important in pancreatic cancer? Ann Surg Oncol 2004 0.83
45 Clinical Stage T1 micropapillary urothelial carcinoma presenting with metastasis to the pancreas. Urology 2011 0.82
46 Management of the Primary Tumor and Limited Metastases in Patients With Metastatic Pancreatic Cancer. J Natl Compr Canc Netw 2015 0.82
47 Weekly paclitaxel, gemcitabine, and external irradiation followed by randomized farnesyl transferase inhibitor R115777 for locally advanced pancreatic cancer. Onco Targets Ther 2012 0.82
48 Partial stomach-partitioning gastrojejunostomy and the success of this procedure in terms of palliation. Am J Surg 2013 0.80
49 Partial stomach-partitioning gastrojejunostomy for malignant duodenal obstruction. Am J Surg 2006 0.80
50 Hydronephrosis does not preclude curative resection of pelvic recurrences after colorectal surgery. Ann Surg Oncol 2005 0.79
51 How to define and manage borderline resectable pancreatic cancer. Surg Clin North Am 2013 0.79
52 Morbidity among long-term survivors after pancreatoduodenectomy for pancreatic adenocarcinoma. Ann Surg Oncol 2014 0.78
53 Editorial: Combined modality treatment of resectable and borderline resectable pancreas cancer: expert consensus conference. Ann Surg Oncol 2009 0.78
54 "Vein involvement during pancreaticoduodenectomy: is there a need for redefinition of borderline resectable disease": a commentary on the article published by Kelly et al. In the Journal of Gastrointestinal Surgery 17:1209 (2013). J Gastrointest Surg 2014 0.77
55 Impact of preoperative therapy on patterns of recurrence in pancreatic cancer. HPB (Oxford) 2013 0.77
56 Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome. Ann Surg Oncol 2006 0.77
57 Neoadjuvant chemoradiation and duration of chemotherapy before surgical resection for pancreatic cancer: does time interval between radiotherapy and surgery matter? Ann Surg Oncol 2013 0.77
58 Five year results of US intergroup/RTOG 9704 with postoperative CA 19-9 ≤90 U/mL and comparison to the CONKO-001 trial. Int J Radiat Oncol Biol Phys 2012 0.75
59 Predictors of Hematologic Toxicity and Chemotherapy Dose Intensity in Patients Undergoing Chemoradiation for Pancreatic Cancer. Am J Clin Oncol 2015 0.75
60 New agents do not necessarily mean progress: potential dangers of the dissecting sealer for pancreaticoduodenectomy. J Am Coll Surg 2006 0.75
61 Pancreaticoduodenectomy after placement of endobiliary metal stents. J Gastrointest Surg 2006 0.75
62 The association of cytokeratin-only-positive sentinel lymph nodes and subsequent metastases in breast cancer. Am J Surg 2005 0.75
63 Neoadjuvant therapy and biliary decompression lower biliary and pancreatic juice vascular endothelial growth factor levels in patients with periampullary adenocarcinoma. Am Surg 2004 0.75
64 Video: laparoscopic right hepatectomy and partial resection of the diaphragm for liver metastases. Surg Endosc 2011 0.75
65 Resection of isolated pelvic recurrences after colorectal surgery: long-term results and predictors of improved clinical outcome. Ann Surg Oncol 2007 0.75